Search Results - "Tsujikawa, Laura"

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease by Gilham, Dean, Wasiak, Sylwia, Tsujikawa, Laura M, Halliday, Christopher, Norek, Karen, Patel, Reena G, Kulikowski, Ewelina, Johansson, Jan, Sweeney, Michael, Wong, Norman C.W

“…Abstract High density lipoproteins (HDL), through activity of the main protein component apolipoprotein A-I (ApoA-I), can reduce the risk of cardiovascular…”
Get full text

Apabetalone downregulates factors and pathways associated with vascular calcification by Gilham, Dean, Tsujikawa, Laura M., Sarsons, Christopher D., Halliday, Christopher, Wasiak, Sylwia, Stotz, Stephanie C., Jahagirdar, Ravi, Sweeney, Michael, Johansson, Jan O., Wong, Norman C.W., Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina

“…Apabetalone is an inhibitor of bromodomain and extraterminal (BET) proteins. In clinical trials, apabetalone reduced the incidence of major adverse cardiac…”
Get full text

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist by McLure, Kevin G, Gesner, Emily M, Tsujikawa, Laura, Kharenko, Olesya A, Attwell, Sarah, Campeau, Eric, Wasiak, Sylwia, Stein, Adam, White, Andre, Fontano, Eric, Suto, Robert K, Wong, Norman C W, Wagner, Gregory S, Hansen, Henrik C, Young, Peter R

“…Increased synthesis of Apolipoprotein A-I (ApoA-I) and HDL is believed to provide a new approach to treating atherosclerosis through the stimulation of reverse…”
Get full text

Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells by Wasiak, Sylwia, Tsujikawa, Laura M., Daze, Emily, Gilham, Dean, Stotz, Stephanie C., Rakai, Brooke D., Sarsons, Chris D., Fu, Li, Azhar, Salman, Jahagirdar, Ravi, Sweeney, Michael, Johansson, Jan O., Wong, Norman C.W., Kulikowski, Ewelina

“…Obese patients are at risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). A lipid-rich diet promotes arterial changes by inducing…”
Get full text

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism by Tsujikawa, Laura M, Fu, Li, Das, Shovon, Halliday, Christopher, Rakai, Brooke D, Stotz, Stephanie C, Sarsons, Christopher D, Gilham, Dean, Daze, Emily, Wasiak, Sylwia, Studer, Deborah, Rinker, Kristina D, Sweeney, Michael, Johansson, Jan O, Wong, Norman C W, Kulikowski, Ewelina

“…Apabetalone (RVX-208) is a bromodomain and extraterminal protein inhibitor (BETi) that in phase II trials reduced the relative risk (RR) of major adverse…”
Get full text

Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators by Tsujikawa, Laura M., Kharenko, Olesya A., Stotz, Stephanie C., Rakai, Brooke D., Sarsons, Christopher D., Gilham, Dean, Wasiak, Sylwia, Fu, Li, Sweeney, Michael, Johansson, Jan O., Wong, Norman C.W., Kulikowski, Ewelina

“…Bromodomain and extraterminal proteins (BETs) are more than just epigenetic regulators of transcription. Here we highlight a new role for the BET protein BRD4…”
Get full text

Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation by Fu, Li, Gilham, Dean, Stotz, Stephanie C., Sarsons, Christopher D., Rakai, Brooke D., Tsujikawa, Laura M., Wasiak, Sylwia, Johansson, Jan O., Sweeney, Michael, Wong, Norman C.W., Kulikowski, Ewelina

“…•Epigenetic inhibitor apabetalone reduces SARS-CoV-2 spike protein binding to ACE2 abundant human lung cells regardless of mutations in Delta and Omicron…”
Get full text

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells by Sarsons, Christopher D, Gilham, Dean, Tsujikawa, Laura M, Wasiak, Sylwia, Fu, Li, Rakai, Brooke D, Stotz, Stephanie C, Carestia, Agostina, Sweeney, Michael, Kulikowski, Ewelina

“…Facioscapulohumeral dystrophy (FSHD) is a muscle disease caused by inappropriate expression of the double homeobox 4 (DUX4) gene in skeletal muscle, and its…”
Get full text

The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation by Wasiak, Sylwia, Fu, Li, Daze, Emily, Gilham, Dean, Rakai, Brooke D., Stotz, Stephanie C., Tsujikawa, Laura M., Sarsons, Chris D., Studer, Deborah, Rinker, Kristina D., Jahagirdar, Ravi, Wong, Norman C. W., Sweeney, Michael, Johansson, Jan O., Kulikowski, Ewelina

“…Brain vascular inflammation is characterized by endothelial activation and immune cell recruitment to the blood vessel wall, potentially causing a breach in…”
Get full text

Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment by Gilham, Dean, Wasiak, Sylwia, Rakai, Brooke D, Fu, Li, Tsujikawa, Laura M, Sarsons, Christopher D, Carestia, Agostina, Lebioda, Kenneth, Johansson, Jan O, Sweeney, Michael, Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina

“…Epigenetic mechanisms are implicated in transcriptional programs driving chronic kidney disease (CKD). Apabetalone is an orally available inhibitor of…”
Get full text

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208) by Wasiak, Sylwia, Gilham, Dean, Tsujikawa, Laura M., Halliday, Christopher, Calosing, Cyrus, Jahagirdar, Ravi, Johansson, Jan, Sweeney, Michael, Wong, Norman C., Kulikowski, Ewelina

“…Apabetalone (RVX-208) is an epigenetic regulator developed to treat cardiovascular disease (CVD) that targets BET proteins. Through transcriptional regulation…”
Get full text

Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease by Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina, Fu, Li, Rakai, Brooke D., Stotz, Stephanie C., Halliday, Christopher, Tsujikawa, Laura M., Daze, Emily, Gilham, Dean, Wasiak, Sylwia, Jahagirdar, Ravi

“…Chronic systemic inflammation contributes to cardiovascular disease (CVD) and correlates with the abundance of acute phase response (APR) proteins in the liver…”
Get full text

Benefit of Apabetalone on Plasma Proteins in Renal Disease by Wasiak, Sylwia, Tsujikawa, Laura M., Halliday, Christopher, Stotz, Stephanie C., Gilham, Dean, Jahagirdar, Ravi, Kalantar-Zadeh, Kamyar, Robson, Richard, Sweeney, Michael, Johansson, Jan O., Wong, Norman C., Kulikowski, Ewelina

“…Apabetalone, a small molecule inhibitor, targets epigenetic readers termed BET proteins that contribute to gene dysregulation in human disorders. Apabetalone…”
Get full text

Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy by Fu, Li, Wasiak, Sylwia, Tsujikawa, Laura M., Rakai, Brooke D., Stotz, Stephanie C., Wong, Norman C. W., Johansson, Jan O., Sweeney, Michael, Mohan, Connie M., Khan, Aneal, Kulikowski, Ewelina

“…Fabry disease (FD) is a rare X‐linked disorder of lipid metabolism, characterized by the accumulation of globotriaosylceramide (Gb3) due to defective the…”
Get full text

Corrigendum to “RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease” [Atherosclerosis 247 (2016) 48–57] by Gilham, Dean, Wasiak, Sylwia, Tsujikawa, Laura M, Halliday, Christopher, Norek, Karen, Patel, Reena G, Kulikowski, Ewelina, Johansson, Jan, Sweeney, Michael, Wong, Norman C.W

Get full text

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes by Wasiak, Sylwia, Gilham, Dean, Tsujikawa, Laura M., Halliday, Christopher, Norek, Karen, Patel, Reena G., McLure, Kevin G., Young, Peter R., Gordon, Allan, Kulikowski, Ewelina, Johansson, Jan, Sweeney, Michael, Wong, Norman C.

“…Apabetalone (RVX-208) inhibits the interaction between epigenetic regulators known as bromodomain and extraterminal (BET) proteins and acetyl-lysine marks on…”
Get full text

Mutational Analysis of Escherichia coli Heat Shock Transcription Factor Sigma 32 Reveals Similarities with Sigma 70 in Recognition of the −35 Promoter Element and Differences in Promoter DNA Melting and −10 Recognition by KOURENNAIA, Olga V, TSUJIKAWA, Laura, DEHASETH, Pieter L

“…Article Usage Stats Services JB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Interaction of RNA Polymerase with Forked DNA: Evidence for Two Kinetically Significant Intermediates on the Pathway to the Final Complex by Tsujikawa, Laura, Tsodikov, Oleg V., deHaseth, Pieter L.

“…RNA polymerase forms competitor-resistant complexes with "forked DNA" templates that are double-stranded from the -35 promoter region through the first base…”
Get full text

EPIGENETIC BET READER INHIBITOR APABETALONE / RVX-208 COUNTERS PROFIBROTIC AND CONTRACTILE ACTIVITY OF CARDIAC FIBROBLASTS WITH POTENTIAL BENEFIT FOR HEART FAILURE by Kulikowski, Ewelina, Wasiak, Sylwia, Tsujikawa, Laura, Fu, Li, Gilham, Dean, Sarsons, Christopher, Sweeney, Michael, Johansson, Jan

Get full text

Apabetalone Reduces Fibrotic Inflammatory and Calcific Factors in Renal Cells and Patient Plasma: FR-PO1052 by Gilham, Dean, Wasiak, Sylwia, Rakai, Brooke D., Fu, Li, Tsujikawa, Laura, Sarsons, Chris, Carestia, Agostina, Lebioda, Kenneth E., Johansson, Jan O., Sweeney, Michael, Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina

Get full text